Key Financial Figures (₹ in Lakhs)

Financial Performance FY 2025-26 vs FY 2024-25:

  • Net Sales: ₹8,975.19 (FY26) vs ₹6,109.76 (FY25) - 46.9% increase
  • Other Operating Income: ₹29.13 (FY26) vs ₹94.81 (FY25)
  • Total Revenue: ₹9,004.32 (FY26) vs ₹6,204.57 (FY25)
  • Other Income: ₹31.72 (FY26) vs ₹78.24 (FY25)
  • Total Expenditure: ₹8,227.08 (FY26) vs ₹6,258.23 (FY25)
  • Profit before Finance Cost, Depreciation, Amortisation and Tax: ₹808.96 (FY26) vs ₹24.57 (FY25)
  • Finance Cost: ₹337.65 (FY26) vs ₹285.72 (FY25)
  • Depreciation and Amortisation Expenses: ₹321.21 (FY26) vs ₹186.76 (FY25)
  • Profit/(Loss) before Tax: ₹150.11 (FY26) vs (₹447.91) (FY25)
  • Current Tax: ₹0 (FY26) vs ₹0 (FY25)
  • Deferred Tax: (₹221.93) (FY26) vs ₹113.95 (FY25)
  • Profit/(Loss) After Tax: ₹372.03 (FY26) vs (₹561.35) (FY25)
  • Other Comprehensive Income: ₹0.78 (FY26) vs (₹2.61) (FY25)
  • Total Comprehensive Income: ₹372.82 (FY26) vs (₹563.96) (FY25)

Balance Sheet Position as at March 31, 2026:

  • Total Assets: ₹6,567.61 Lakhs
  • Equity Share Capital: ₹2,442.93 Lakhs (2,44,29,280 equity shares of ₹10 each)
  • Other Equity: ₹1,451.02 Lakhs
  • Long Term Borrowings: ₹1,475.99 Lakhs
  • Short Term Borrowings: ₹358.37 Lakhs
  • Trade Payables: ₹690.61 Lakhs
  • Current Ratio: 2.76

Operational Highlights

Capacity Expansion:

The company is undertaking a 3x capacity expansion project with detailed product-wise capacity increases:

| Product | Current Capacity (tons) | Post-Expansion Capacity (tons) |

| SMP | 980 | 3,055 |

| Casein | 850 | 1,250 |

| WHEY Powder A | 1,155 | 2,030 |

| MPC | 180 | 255 |

| WHEY Powder S | 198 | 660 |

| DW | 209 | 463 |

| Sodium Caseinate | 19 | 511 |

| Butter | 200 | 3,600 |

| Fat Filled Powders | 83 | 1,245 |

| TOTAL | 3,873 | 13,068 |

Product Portfolio:

The company manufactures various dairy products including Skimmed Milk Powder, Milk Protein Concentrates, Whey Powder, Casein, Sodium Caseinate, and Fat Filled Powders. Applications span nutrition/pharma industry, dairy industry, chocolates, baked foods, food ingredients, ice cream, and industrial products.

Market Position:

  • India's only native MPC (Milk Protein Concentrate) maker
  • Producer of Infant Milk Powders with Micro-Encapsulated Fat technology
  • Products sold under brands Formula 7+, Formula 8, Formula 8+, and retail brand ActivDay PRIME

AGM Details and Resolutions

16th Annual General Meeting:

  • Date: September 30, 2026
  • Time: 3:30 PM
  • Mode: Video Conferencing/Other Audio Visual Means
  • Record Date: September 23, 2026
  • Register Closure: September 24-30, 2026

Ordinary Business Resolutions:

1. Adoption of Financial Statements for FY 2025-26

2. Re-appointment of Mrs. Rajadharshini Rajasekaran as Non-Executive Director liable to retire by rotation

3. Re-appointment of M/s VSSR & Co as Statutory Auditors for 5 years until 21st AGM

Special Business Resolutions:

4. Regularization of Dr. Karthik Neelakandan as Director (appointed w.e.f September 08, 2026)

5. Approval of material related party transactions with A R Dairy Food Private Limited up to ₹60 Crores

6. Revision of remuneration payable to Mr. R Rajasekaran, Chairman & Managing Director and continuation of directorship after attaining 70 years of age

Related Party Transactions

With A R Dairy Food Private Limited:

  • Proposed aggregate transactions: ₹60 Crores for period until 17th AGM
  • Nature: Purchase of Milk & Milk Products and Dairy Processing services
  • Percentage of company's annual turnover: 67%
  • Relationship: Group Company (Raju Rajasekaran is Managing Director of both companies)

Director Changes and Remuneration

Board Changes:

  • Mr. Ravi Rajappa ceased as Director w.e.f September 08, 2026
  • Dr. Karthik Neelakandan appointed as Additional Director w.e.f September 08, 2026
  • Mr. Ravi Chandran Ranganathan appointed as Chief Executive Officer w.e.f September 08, 2026

Revised Remuneration for Chairman & MD:

  • Effective from October 1, 2026: ₹5 lakhs per month
  • Additional perquisites: PF contributions, gratuity, leave encashment
  • Total remuneration not to exceed 5% of net profits
  • Special resolution required for continuation beyond age of 70 years (attained on June 15, 2026)

Corporate Governance

Board Committees:

  • Audit Committee: Mrs. B N Padmaja Priyadarshini (Chairperson), Mr. N M Ranganathan, Mr. R Rajasekaran
  • Nomination and Remuneration Committee: Mrs. B N Padmaja Priyadarshini (Chairperson), Mr. N M Ranganathan, Dr. Karthik Neelakandan
  • Stakeholder's Relationship Committee: Mr. N M Ranganathan (Chairman), Mrs. B N Padmaja Priyadarshini, Mrs. Rajadharshini Rajasekaran
  • CSR Committee: Mr. R Rajasekaran, Mrs. Rajadharshini Rajasekaran, Mr. N M Ranganathan

Key Managerial Personnel:

  • Mr. G U K Narayanan - Company Secretary & Compliance Officer
  • Mr. Ravi Chandran Ranganathan - Chief Executive Officer
  • Mrs. Velvizhi Ganesan - Chief Financial Officer

Auditor Appointments

Statutory Auditor:

M/s VSSR & Co, Chartered Accountants (FRN: 016495S) re-appointed for 5 years until 21st AGM

Secretarial Auditor:

Mr. S Muthu Raju, Practicing Company Secretary

Internal Auditor:

M/s C S N K & Co, Chartered Accountants

Shareholding Pattern

Promoter Holding:

Total promoter holding: 0.59% (145.02 lakh shares)

Major promoters:

  • Indrayani Biotech Limited: 0.31%
  • R Rajasekaran: 0.08%
  • R Rajadharshini: 0.06%
  • R Ravichandran: 0.05%

Other Significant Disclosures

Dividend:

No dividend recommended for FY 2025-26 due to fund requirements for growth

Public Deposits:

No deposits accepted from public during FY 2025-26

CSR Expenditure:

Not applicable as net profit didn't exceed ₹5 crores in previous three consecutive financial years

ESG Initiatives:

  • Smart water recycling systems
  • Affordable nutrition access programs
  • Rural community empowerment
  • Renewable energy adoption (wind and solar power)

Foreign Exchange:

  • Earnings: ₹49.18 lakhs (FY26) vs ₹53.72 lakhs (FY25)
  • Outgo: ₹19.65 lakhs (FY26) vs ₹379.19 lakhs (FY25)

#Tags: #DindigulFarmProduct #SEBIDisclosure #AnnualReport #FY2026Results #RegulatoryCompliance #FinancialUpdate #Neutral